Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) were up 2.3% on Wednesday . The company traded as high as $3.69 and last traded at $3.63, with a volume of 132,161 shares traded. The stock had previously closed at $3.55.

A number of analysts have recently weighed in on DRNA shares. Leerink Swann reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Thursday, June 30th. Jefferies Group reissued a “buy” rating and issued a $19.00 price objective on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. Chardan Capital lowered their price objective on Dicerna Pharmaceuticals from $4.00 to $3.50 and set a “neutral” rating for the company in a research report on Monday, August 8th. Stifel Nicolaus lowered their price objective on Dicerna Pharmaceuticals from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, May 10th. Finally, Cowen and Company reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Sunday, June 26th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Dicerna Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $11.85.

The stock’s market capitalization is $75.33 million. The company has a 50 day moving average price of $3.33 and a 200 day moving average price of $4.33.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.09. Equities analysts forecast that Dicerna Pharmaceuticals Inc. will post ($3.17) earnings per share for the current year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.